AbbVie (NYSE:ABBV) Issues Q1 2026 Earnings Guidance
by Mitch Edgeman · The Markets DailyAbbVie (NYSE:ABBV – Get Free Report) updated its first quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 2.560-2.600 for the period, compared to the consensus estimate of 3.010. The company issued revenue guidance of -. AbbVie also updated its FY 2026 guidance to 13.960-14.160 EPS.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on ABBV. Barclays began coverage on AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. Royal Bank Of Canada began coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.00.
Get Our Latest Stock Report on AbbVie
AbbVie Trading Down 0.4%
ABBV stock traded down $0.86 during trading on Friday, reaching $211.54. The stock had a trading volume of 274,100 shares, compared to its average volume of 7,130,790. AbbVie has a 52 week low of $168.54 and a 52 week high of $244.81. The stock’s 50 day moving average is $220.65 and its two-hundred day moving average is $224.11. The firm has a market cap of $374.04 billion, a PE ratio of 89.89, a PEG ratio of 0.76 and a beta of 0.38.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the company earned $2.16 earnings per share. AbbVie’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie will post 12.31 EPS for the current year.
AbbVie Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio is currently 293.22%.
Insider Transactions at AbbVie
In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.
Key Headlines Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie sued HHS and the federal government seeking a narrower definition of who qualifies as a 340B patient — a move that, if upheld, could reduce discounted sales and protect revenue/margins. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
- Positive Sentiment: Dividend resilience remains a tailwind: AbbVie’s payout history and yield keep it appealing to income investors, supporting downside defense in the stock. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
- Neutral Sentiment: Analyst takes are mixed: some outlets frame ABBV as fairly valued or a buy with caveats, highlighting pipeline potential (immunology drugs Skyrizi/Rinvoq) but also valuation and competition concerns. AbbVie: Fairly Valued And Positioned For Growth
- Neutral Sentiment: Marketing/competitive signals: J&J recently retook the top spot in TV drug ad spending from AbbVie — a tactical datapoint about promotional intensity but not an immediate earnings driver. J&J’s Tremfya retakes TV drug ad spending crown from AbbVie
- Negative Sentiment: AbbVie cut its Q1 2026 EPS guidance to $2.56–$2.60 (consensus ~3.01) and FY 2026 to $13.96–$14.16 (consensus ~14.56), a direct driver of today’s downward pressure as investors re-rate near-term earnings visibility.
- Negative Sentiment: Cantor Fitzgerald lowered its price target on ABBV to $240 from $250 and warned Q1 likely won’t “dramatically reinvigorate” the story — a notable sell-side tilt that can amplify short-term selling. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
Institutional Trading of AbbVie
A number of hedge funds and other institutional investors have recently bought and sold shares of ABBV. Brighton Jones LLC increased its position in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC increased its position in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. grew its position in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares in the last quarter. Ieq Capital LLC grew its position in shares of AbbVie by 4.6% during the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after purchasing an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC grew its position in shares of AbbVie by 117.3% during the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after purchasing an additional 612,702 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.